Published online before print February 1, 2007, doi: 10.1161/01.STR.0000258356.68323.6d
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2007;38:1113.)
© 2007 American Heart Association, Inc.
Cochrane Corner |
Glycoprotein IIb-IIIa Inhibitors for Acute Ischemic Stroke
From the Stroke Unit, "Niguarda Ca’ Granda" Hospital (A.C., I.S.), Milan, Italy; and the Epidemiology Department (I.A.), Regional Health Authority of Umbria, Perugia.
Correspondence to Alfonso Ciccone, Stroke Unit, "Niguarda Ca’ Granda" Hospital, Piazza Ospedale Maggiore 3, Milan, Italy 20162. E-mail alfonso.ciccone@ospedaleniguarda.it
Section Editor: Graeme J. Hankey MD, FRCP
Key Words: acute stroke • antiplatelet agents • antiplatelet drugs • brain infarction • brain ischemia • cerebral infarct • cerebrovascular accident • platelet inhibitors • randomized controlled trials • stroke management • therapy • thrombosis • glycoprotein IIb-IIIa inhibitors • meta-analysis • systematic review
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
Glycoprotein (GP) IIb-IIIa inhibitors block the final common pathway to platelet aggregation antagonizing with receptors that bind fibrinogen molecules forming bridges between adjacent platelets. Thus, GP IIb-IIIa inhibitors could favor endogenous thrombolysis by reducing thrombus growth and prevent thrombus reformation by competitive inhibition with fibrinogen. Currently used in clinical practice for acute coronary syndromes and percutaneous coronary interventions, they could be useful also for patients with acute ischemic stroke.
|
Objective |
|---|
To perform a systematic review of controlled clinical trials in order to assemble all the available data to evaluate the potential efficacy and safety of GP IIb-IIIa inhibitors in patients with acute ischemic stroke.
|
Search Strategy |
|---|
We searched the Cochrane Stroke Group Trials Register (last searched May 31, 2005). In addition we searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library, 2005 Issue 2), MEDLINE (1966 to June 2005) and EMBASE (1980 to June 2005). In an effort to identify further published, unpublished and ongoing trials we searched reference lists and contacted authors and pharmaceutical companies.
|
Selection Criteria |
|---|
We aimed to analyze unconfounded randomized controlled trials comparing GP IIb-IIIa inhibitors with placebo in patients with acute ischemic stroke. Only patients who started the treatment within 6 hours of stroke onset were included.
|
Data Collection and Analysis |
|---|
Three reviewers independently selected trials for inclusion, assessed trial quality and extracted the data.
|
Main Results |
|---|
Two trials involving 474 patients were included. Only data on 414 patients treated within 6 hours were considered. Patients were treated with intravenous abciximab or placebo. Treatment with abciximab was associated with a nonsignificant reduction of
This article has been cited by other articles:
 |
|
 |
|
  G. Stoll, C. Kleinschnitz, and B. Nieswandt Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment Blood, November 1, 2008; 112(9): 3555 - 3562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF]
|
|